Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation.

Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation. Oncol Lett. 2019 Dec;18(6):6187-6195 Authors: Hu Z, Guo J, Zhao M, Jiang T, Yang X Abstract Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer (PC) after chemotherapy and prognostic correlation were explored. Eighty-four patients with PC undergoing chemotherapy in The Third Affiliated Hospital of Qiqihar Medical University from January 2016 to January 2017 were enrolled as the observation group treated with DP regimen, and further 100 healthy individuals undergoing physical examination were enrolled as the control group. RT-qPCR was used to detect expression of serum miR-129 and miR-139. According to the clinical efficacy after treatment, patients with complete remission (CR) and partial remission (PR) were considered as a good curative effect group, whereas those with stable disease (SD) and progressive disease (PD) were considered as a poor curative effect group. In the observation group, miR-129 and miR-139 expression after treatment was significantly lower and higher, respectively, than that before treatment (P
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

This is the first national audit report on process and outcome measures from all aspects of the care pathway for men with prostate cancer. The information presented compares prostate cancer services locally and nationally, including access to chemotherapy.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Source: BMJ News - Category: General Medicine Source Type: research
ConclusionOur modeling and simulation framework can be applied to support indirect comparison, dose selection, and go/no-go decision-making for new agents targeting CRPC.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Title: Prostate Cancer Treatment: Chemotherapy, Bone-Targeted and Immune TherapyCategory: Diseases and ConditionsCreated: 1/9/2020 12:00:00 AMLast Editorial Review: 1/9/2020 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
ConclusionsAdjuvant chemotherapy in high-risk prostate cancer using docetaxel and prednisone did not lead to statistically significant improvement in PFS for the intention-to-treat population as a whole. The analysis was challenged by lower power due to accrual limitation. Subgroup analyses suggest potential benefit for patients with Gleason grade ≤7 and stage ≥ pT3b (ClinicalTrials.gov number NCT00132301).Patient summaryIn this randomized trial, we tested whether addition of chemotherapy to surgery for high-risk prostate cancer decreased the risk of prostate-specific antigen rise after surgery. We found no...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conditions:   Prostate Cancer;   Chemotherapy Effect;   Hormone Sensitive Prostate Cancer;   Locally Advanced Prostate Carcinoma Interventions:   Drug: Neoadjuvant chemotherapy combined with hormone therapy;   Drug: Neoadjuvant hormone therapy;   Procedure: Radical Prostatectomy (RP)+ extended lymph node dissection Sponsor:   RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(N.N.Aleksandrov National Cancer Center of Belarus) N. N. The Alexandrov National Cancer Centre begins phase II case-control clinical trial of its immuno-oncology agent, Elenagen. Inoperable late-stage cancer patients with triple-negative breast cancer, ovarian cancer, stomach cancer or prostate cancer will be randomized and then subsequently receive either standard chemotherapy or chemotherapy combined with Elenagen.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Cascante M Abstract Platinum-based chemotherapy persists to be the only effective therapeutic option against a wide variety of tumours. Nevertheless, the acquisition of platinum resistance is utterly common, ultimately cornering conventional platinum drugs to only palliative in many patients. Thus, encountering alternatives that are both effective and non-cross-resistant is urgent. In this work, we report the synthesis, reduction studies and luminescent properties of a series of cyclometallated (C,N,N') PtIV compounds derived from amine-imine ligands, and their remarkable efficacy at the high nanomolar range and ...
Source: Chemistry - Category: Chemistry Authors: Tags: Chemistry Source Type: research
Authors: Spratt DE Abstract While the DNA of a tumor is often equated to a fingerprint or its unique genetic identify, a tumor's RNA profile represents a complex dynamic state more akin to a tumors personality or distinct behavior. Of the 11 types of RNA, the translational and clinical focus in prostate cancer has been primarily on mRNA and lncRNA. The most common use of RNA-based biomarkers is to assess a tumor's aggressiveness or treatment sensitivity. However, multiple gene expression signatures have been developed to capture the functional state that results from canonical DNA alterations, including ERG fusions...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 castration-resistant prostate carcinoma patients treated with 225Ac-PSMA-617, identifying variables predictive for overall survival (OS) and progression-free survival (PFS) after 225Ac-PSMA-617 treatment. Methods: 225Ac-PSMA-617 was administered to patients who had metastatic castration-resistant prostate carcinoma and who had exhausted available therapy options for their disease. Full blood count, glomerular...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Prostate Cancer